Astellas Signs Novel Development Pact | Chemical & Engineering News
Volume 91 Issue 19 | p. 25 | Concentrates
Issue Date: May 13, 2013

Astellas Signs Novel Development Pact

Department: Business
Keywords: research, development, investment

Astellas and Drais Pharmaceuticals will collaborate on the development of an Astellas compound that treats nocturia, a sleep disorder. Under the agreement, Astellas will license ASP7035, currently in Phase II clinical trials, to Tacurion Pharma, a virtual company operated by Drais. The deal is similar to two others Astellas entered with other Drais-run virtual companies, Telsar Pharma and Seldar Pharma, to develop drugs for ulcerative colitis and inflammatory bowel disease. Astellas and two venture capital firms, InterWest Partners and Sutter Hill Ventures, will invest a total of $15 million in Tacurion.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment